Literature DB >> 23917076

Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells.

Jianmin Wu1, Xue-Jiao Zhang, Ke-Qing Shi, Yong-Ping Chen, Yong-Feng Ren, Yi-Jiang Song, Guiling Li, Yong-Feng Xue, Yu-Xiao Fang, Zhu-Jun Deng, Xiaoling Xu, Jimin Gao, Kai-Fu Tang.   

Abstract

Hepatitis B surface antigen (HBsAg) seropositivity is an important risk factor for hepatocellular carcinoma (HCC), and HBsAg-transgenic mice have been reported to spontaneously develop HCC. The major histocompatibility complex class I-related molecules A and B (MICA and MICB) are NKG2D ligands that play important roles in tumor immune surveillance. In the present study, we found that HBsAg overexpression in HepG2 cells led to upregulation of 133 and downregulation of 9 microRNAs (miRNAs). Interestingly, several HBsAg-induced miRNAs repressed the expression of MICA and MICB via targeting their 3'-untranslated regions. In addition, the expression of MICA and MICB was significantly reduced upon HBsAg overexpression, which was partially restored by inhibiting the activities of HBsAg-induced miRNAs. Moreover, HBsAg-overexpressing HCC cells exhibited reduced sensitivity to natural killer cell-mediated cytolysis. Taken together, our data suggest that HBsAg supresses the expression of MICA and MICB via induction of cellular miRNAs, thereby preventing NKG2D-mediated elimination of HCC cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917076     DOI: 10.1093/carcin/bgt268

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  23 in total

Review 1.  Hepatocytes as Immunological Agents.

Authors:  Ian N Crispe
Journal:  J Immunol       Date:  2016-01-01       Impact factor: 5.422

2.  Role natural killer group 2D-ligand interactions in hepatitis B infection.

Authors:  Teresa Pollicino; Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-04-28

Review 3.  Mechanisms of Hepatitis B Virus Persistence.

Authors:  Kuen-Nan Tsai; Cheng-Fu Kuo; Jing-Hsiung James Ou
Journal:  Trends Microbiol       Date:  2017-08-16       Impact factor: 17.079

Review 4.  MICA SNPs and the NKG2D system in virus-induced HCC.

Authors:  Kaku Goto; Naoya Kato
Journal:  J Gastroenterol       Date:  2014-10-01       Impact factor: 7.527

Review 5.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.

Authors:  Jason Lamontagne; Laura F Steel; Michael J Bouchard
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

6.  microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.

Authors:  Haitao Xie; Qiugui Zhang; Hui Zhou; Jun Zhou; Ji Zhang; Yan Jiang; Jinghong Wang; Xianglin Meng; Leping Zeng; Xiaoxin Jiang
Journal:  Cytotechnology       Date:  2017-05-26       Impact factor: 2.058

Review 7.  Occult hepatitis B - the result of the host immune response interaction with different genomic expressions of the virus.

Authors:  George Sebastian Gherlan
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

8.  Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women.

Authors:  Yang Yang; Jing Gao; Hong-Lan Li; Wei Zheng; Gong Yang; Wei Zhang; Xiao Ma; Yu-Ting Tan; Nathaniel Rothman; Yu-Tang Gao; Wong-Ho Chow; Xiao-Ou Shu; Yong-Bing Xiang
Journal:  Int J Cancer       Date:  2016-03-30       Impact factor: 7.396

9.  The clinical and biological significance of MICA in clear cell renal cell carcinoma patients.

Authors:  Xiang Zhang; Lei Yan; Wei Jiao; Juchao Ren; Naidong Xing; Yongzhen Zhang; Yuanwei Zang; Jue Wang; Zhonghua Xu
Journal:  Tumour Biol       Date:  2015-09-09

10.  BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA.

Authors:  Mengyao Qian; Jingwen Geng; Kaili Luo; Zheng Huang; Qinkai Zhang; Jian-An Zhang; Liying Ji; Jianmin Wu
Journal:  Oncogene       Date:  2019-10-31       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.